F-Prime Capital

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.

1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, founded in 2017. It operates a health data aggregation and centralization platform that facilitates the secure transmission of medical data between health systems and consumer applications. The platform consolidates health information from various electronic medical record systems, allowing users to control and share their digital health records with healthcare providers. Additionally, it enables providers to access and query the most current patient data from multiple connected health systems. The platform also supports software developers by providing access to clinical data from various clinics and hospitals, ultimately aiming to improve healthcare outcomes and reduce costs through better data utilization.

Vendr, Inc. is a Boston-based company that provides a software-as-a-service solution designed to manage the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr specializes in commercial negotiations, renewal management, and contract logistics, enabling companies to streamline their software acquisition efforts. By assisting organizations in purchasing and renewing software, Vendr helps them save both time and money, making it an essential partner for scaling companies. Its services are utilized by a range of fast-growing business-to-business and business-to-consumer companies, highlighting its effectiveness in the software procurement landscape.

Proximie Inc., based in Bedford, Massachusetts, offers a secure software platform that facilitates virtual surgical collaboration among surgeons. By leveraging advanced telecommunication, augmented reality, artificial intelligence, and machine learning technologies, Proximie's platform enables real-time, peer-to-peer assistance during surgeries, regardless of location. This innovative approach allows surgeons to share expertise before, during, and after procedures, effectively overcoming the barriers of time and distance. Furthermore, the platform is compatible with various devices and software used in operating rooms, allowing for seamless integration and interaction. Proximie's mission is to enhance surgical knowledge and skills, enabling surgeons to refine their techniques in diverse settings, even with limited bandwidth.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.

Proof Diagnostics focuses on developing CRISPR-based molecular tests for the detection of COVID-19. The company aims to empower communities by providing rapid diagnostic kits that enable medical professionals to effectively test patients for coronavirus infections. By leveraging advanced genetic technologies, Proof Diagnostics contributes to improved health outcomes and better management of infectious diseases.

Eleos Health is a company that develops a software-as-a-service (SaaS) tool focused on mental health. Utilizing artificial intelligence and voice technology, Eleos Health's platform operates in the background during mental health sessions to gather insights into a patient's behavioral health. By analyzing voice interactions and various data parameters, the tool provides valuable information that enables clinicians to deliver personalized care and support tailored to individual patient needs.

Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants.

RightHand Robotics, Inc. specializes in manufacturing robotic order-picking systems designed for various industrial applications, including e-commerce, food handling, and flexible manufacturing. The company offers innovative products such as the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that enhances the robots' ability to grasp items gently and make adjustments to avoid errors. Their technology allows robots to automatically grasp a wide range of items from bins and cases, eliminating the need for extensive data-entry or parameter-tuning, thereby making the systems cost-effective and adaptable to the evolving needs of businesses. Founded in 2015, RightHand Robotics is headquartered in Cambridge, Massachusetts, with a sales and business development office located in Frankfurt, Germany.

K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.

Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Zus Health is a developer of a healthcare data platform designed to enhance digital health by facilitating the creation of customized technologies and services. The platform connects both health and non-health information, offering a comprehensive view of patients while allowing for the sharing of clinical and non-clinical data without the need for shared applications. By removing traditional barriers in healthcare technology development, Zus Health empowers healthcare professionals to develop solutions that are more affordable and tailored to individual needs, ultimately aiming to improve the overall healthcare experience.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

Proximie Inc., based in Bedford, Massachusetts, offers a secure software platform that facilitates virtual surgical collaboration among surgeons. By leveraging advanced telecommunication, augmented reality, artificial intelligence, and machine learning technologies, Proximie's platform enables real-time, peer-to-peer assistance during surgeries, regardless of location. This innovative approach allows surgeons to share expertise before, during, and after procedures, effectively overcoming the barriers of time and distance. Furthermore, the platform is compatible with various devices and software used in operating rooms, allowing for seamless integration and interaction. Proximie's mission is to enhance surgical knowledge and skills, enabling surgeons to refine their techniques in diverse settings, even with limited bandwidth.

1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, founded in 2017. It operates a health data aggregation and centralization platform that facilitates the secure transmission of medical data between health systems and consumer applications. The platform consolidates health information from various electronic medical record systems, allowing users to control and share their digital health records with healthcare providers. Additionally, it enables providers to access and query the most current patient data from multiple connected health systems. The platform also supports software developers by providing access to clinical data from various clinics and hospitals, ultimately aiming to improve healthcare outcomes and reduce costs through better data utilization.

Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, that specializes in primary health care services through an artificial intelligence-based platform. Founded in 2016, the company aims to redefine patient care by providing a virtual-first approach that combines advanced technology with a dedicated care team. Firefly Health offers services for common health conditions such as back pain, stomach flu, and women's health issues, facilitating live video appointments with primary care physicians without any membership fees. This model allows patients to navigate their health more effectively and make informed decisions, while enabling healthcare professionals to deliver consistent and proactive care.

Vendr, Inc. is a Boston-based company that provides a software-as-a-service solution designed to manage the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr specializes in commercial negotiations, renewal management, and contract logistics, enabling companies to streamline their software acquisition efforts. By assisting organizations in purchasing and renewing software, Vendr helps them save both time and money, making it an essential partner for scaling companies. Its services are utilized by a range of fast-growing business-to-business and business-to-consumer companies, highlighting its effectiveness in the software procurement landscape.

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

Atalanta Therapeutics is a biotechnology company focused on developing innovative treatment options for neurodegenerative diseases through its proprietary RNA interference platform. The company aims to create therapeutics that target various conditions, including Huntington's disease by specifically targeting the HTT gene. By addressing the underlying causes of these diseases, Atalanta Therapeutics seeks to provide clinicians with effective strategies to halt disease progression and improve patient outcomes.

Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.

Citrine Medicine is a rare disease-focused pharmaceutical firm.

WellAir Group Limited specializes in designing and manufacturing portable air disinfection units, HVAC air purification devices, and sensors aimed at improving indoor air quality. The company's products effectively remove airborne pollutants and pathogens, including viruses, bacteria, allergens, and mold. WellAir markets its offerings under the Novaerus and Plasma-Air brand names, serving a diverse clientele that includes hospitals, senior living facilities, schools, casinos, railway stations, residences, and industrial facilities. Its Novaerus Portables are medical-grade air disinfection units that deactivate airborne pathogens while neutralizing volatile organic compounds. The Plasma-Air HVAC systems utilize plasma-generated bipolar ionization to diminish particulate matter, odors, viruses, and bacteria. Additionally, WellAir manufactures sensors and provides a web-based monitoring portal that tracks outdoor air pollution, flu levels, pollen counts, and weather conditions. Founded in 2012 and based in Dublin, Ireland, WellAir is dedicated to creating safe indoor environments for the health and well-being of individuals.

RightHand Robotics, Inc. specializes in manufacturing robotic order-picking systems designed for various industrial applications, including e-commerce, food handling, and flexible manufacturing. The company offers innovative products such as the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that enhances the robots' ability to grasp items gently and make adjustments to avoid errors. Their technology allows robots to automatically grasp a wide range of items from bins and cases, eliminating the need for extensive data-entry or parameter-tuning, thereby making the systems cost-effective and adaptable to the evolving needs of businesses. Founded in 2015, RightHand Robotics is headquartered in Cambridge, Massachusetts, with a sales and business development office located in Frankfurt, Germany.

Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.

Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.

PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to developing targeted therapies for rare disorders, particularly those associated with neurofibromatosis type 1 and related conditions. The company specializes in creating novel therapies aimed at addressing the needs of patients suffering from immunosuppressant-mediated squamous cell carcinoma and congenital birthmarks, including keratinocytic epidermal nevi and nevus sebaceous. NFlection focuses on first-in-class MEK inhibitors that target the aberrant activation of the Ras/Raf/MEK/ERK pathway, which is central to these disorders. Founded in 2014 and headquartered in Wayne, Pennsylvania, NFlection Therapeutics is committed to advancing treatments that can significantly impact the lives of patients with these challenging conditions.

NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.

Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

Wellframe Inc. is a digital health management company based in Boston, Massachusetts, that specializes in care management solutions and digital concierge services. Founded in 2011, Wellframe develops mobile patient engagement software that enhances care management by connecting patients with their care teams through a user-friendly mobile application. The platform utilizes real-time member-generated data and artificial intelligence to create personalized care protocols and facilitate two-way communication, allowing for timely interventions and better patient monitoring. Wellframe's offerings include health plan solutions, such as daily health reporting, care team dashboards, and omni-channel communication tools, as well as operational services like system integration and analytics. Additionally, the company provides strategic consulting and change management services to help healthcare organizations improve their care delivery and patient engagement processes.

Vendr, Inc. is a Boston-based company that provides a software-as-a-service solution designed to manage the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr specializes in commercial negotiations, renewal management, and contract logistics, enabling companies to streamline their software acquisition efforts. By assisting organizations in purchasing and renewing software, Vendr helps them save both time and money, making it an essential partner for scaling companies. Its services are utilized by a range of fast-growing business-to-business and business-to-consumer companies, highlighting its effectiveness in the software procurement landscape.

Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, that specializes in primary health care services through an artificial intelligence-based platform. Founded in 2016, the company aims to redefine patient care by providing a virtual-first approach that combines advanced technology with a dedicated care team. Firefly Health offers services for common health conditions such as back pain, stomach flu, and women's health issues, facilitating live video appointments with primary care physicians without any membership fees. This model allows patients to navigate their health more effectively and make informed decisions, while enabling healthcare professionals to deliver consistent and proactive care.

Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.

Optimus Ride is a self-driving vehicle company based in Boston, Massachusetts, that focuses on developing technologies for efficient, sustainable, and equitable mobility systems. As a spinoff from the Massachusetts Institute of Technology, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and mobility-on-demand systems. Its technology integrates advancements in sensor fusion, mapping, computer vision, and machine learning, tailored for geofenced environments. The team comprises individuals with extensive industrial and entrepreneurial experience in areas such as manufacturing robotics, urban design, and shared vehicle fleet management, enabling diverse applications ranging from commercial vessel operations to transit solutions.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.

Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.

Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.

Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Nebula Genomics, founded in 2016 and based in San Francisco, California, is a company focused on human genome sequencing and health data. It aims to create a comprehensive and trusted marketplace for genomic and health data, facilitating access for consumers, researchers, and the medical community. Utilizing blockchain technology, Nebula Genomics empowers individuals to control their genomic data while receiving compensation for its use. The marketplace aggregates extensive genetic information, which researchers can analyze to enhance drug development and streamline clinical trials, ultimately contributing to personalized medicine. The company's innovative DNA sequencing technology allows for the examination of all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, enabling clients to explore genetic variants comprehensively. Nebula Genomics was co-founded by Harvard genomics pioneer George Church and has received backing from notable investors.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

TraceLink, Inc. specializes in providing track and trace network solutions that enhance the life sciences supply chain and combat counterfeit prescription drugs. The company offers a range of products, including pharmaceutical serialization, drug tracking, and compliance solutions through its TraceLink Life Sciences Cloud. Key offerings include the Smart Rx Manager, which helps healthcare providers comply with the European Union Falsified Medicines Directive, and Serialized Product Intelligence, a cloud application that utilizes serialization data to identify supply chain issues and optimize operations. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers, and has established strategic partnerships with notable firms such as Amazon and KPMG. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink also has offices in the United Kingdom, India, Singapore, and Brazil. The company's platform is recognized for its ability to deliver global connectivity and visibility across the pharmaceutical supply chain, ensuring compliance and improving operational efficiency.

Flywire operates an online payment platform that facilitates both domestic and international transactions, catering primarily to the education and healthcare sectors. The platform enables users, including international students and patients seeking medical care abroad, to make payments in various currencies through familiar online and offline options. By leveraging vertical-specific insights and technology, Flywire streamlines the payment process and enhances operational efficiency while minimizing risks associated with invoicing and payment reconciliation. The company, which was founded in 2009 and is headquartered in Boston, Massachusetts, has established partnerships with TRUE North and Adyen to bolster its offerings. With a significant portion of its revenue generated from the Americas, Flywire continues to expand its services to meet the needs of its diverse clientele.

Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.

NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

TraceLink, Inc. specializes in providing track and trace network solutions that enhance the life sciences supply chain and combat counterfeit prescription drugs. The company offers a range of products, including pharmaceutical serialization, drug tracking, and compliance solutions through its TraceLink Life Sciences Cloud. Key offerings include the Smart Rx Manager, which helps healthcare providers comply with the European Union Falsified Medicines Directive, and Serialized Product Intelligence, a cloud application that utilizes serialization data to identify supply chain issues and optimize operations. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers, and has established strategic partnerships with notable firms such as Amazon and KPMG. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink also has offices in the United Kingdom, India, Singapore, and Brazil. The company's platform is recognized for its ability to deliver global connectivity and visibility across the pharmaceutical supply chain, ensuring compliance and improving operational efficiency.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.

Kyruus, Inc. is a provider of web-based software solutions focused on optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010 and headquartered in Boston, Massachusetts, Kyruus offers a suite of analytically driven products designed to enhance the engagement, management, and performance of healthcare providers. Its solutions include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which provides administrators with tools to monitor and analyze physician performance. Additionally, the company offers Kyruus MDSeekyr for identifying high-value providers and Kyruus Insight Reports for evaluating physician network trends and performance. The ProviderMatch suite further aids hospitals in connecting patients with the most suitable providers, ensuring a seamless patient experience while aligning provider availability with patient demand. Through its proprietary data management platform, Kyruus leverages accurate data to facilitate effective appointments and enhance overall patient care.

Nebula Genomics, founded in 2016 and based in San Francisco, California, is a company focused on human genome sequencing and health data. It aims to create a comprehensive and trusted marketplace for genomic and health data, facilitating access for consumers, researchers, and the medical community. Utilizing blockchain technology, Nebula Genomics empowers individuals to control their genomic data while receiving compensation for its use. The marketplace aggregates extensive genetic information, which researchers can analyze to enhance drug development and streamline clinical trials, ultimately contributing to personalized medicine. The company's innovative DNA sequencing technology allows for the examination of all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, enabling clients to explore genetic variants comprehensively. Nebula Genomics was co-founded by Harvard genomics pioneer George Church and has received backing from notable investors.

Valor Performance is digital learning platform focused on igniting and sustaining peak performance for managers and executives. Valor closes the professional training gap through a dynamic digital platform, progress metrics, and personalized programs for all Valor recipients – giving them a premium experience while fostering a performance mindset. Founded in 2017, Valor Performance is headquartered in Boston, Massachusetts.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Valor Performance is digital learning platform focused on igniting and sustaining peak performance for managers and executives. Valor closes the professional training gap through a dynamic digital platform, progress metrics, and personalized programs for all Valor recipients – giving them a premium experience while fostering a performance mindset. Founded in 2017, Valor Performance is headquartered in Boston, Massachusetts.

Threat Stack specializes in providing security solutions tailored for cloud infrastructure, enabling DevOps and SecOps teams to innovate and scale securely. The Threat Stack Cloud Security Platform and Cloud SecOps Program are designed to address complex cloud security needs by delivering continuous security monitoring and risk assessment. This approach helps organizations identify and verify insider threats, external attacks, and compliance gaps in real-time. By focusing on cloud, hybrid-cloud, and containerized environments, Threat Stack empowers security and operations teams to effectively manage risk and compliance across their entire infrastructure.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.

Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

Wellframe Inc. is a digital health management company based in Boston, Massachusetts, that specializes in care management solutions and digital concierge services. Founded in 2011, Wellframe develops mobile patient engagement software that enhances care management by connecting patients with their care teams through a user-friendly mobile application. The platform utilizes real-time member-generated data and artificial intelligence to create personalized care protocols and facilitate two-way communication, allowing for timely interventions and better patient monitoring. Wellframe's offerings include health plan solutions, such as daily health reporting, care team dashboards, and omni-channel communication tools, as well as operational services like system integration and analytics. Additionally, the company provides strategic consulting and change management services to help healthcare organizations improve their care delivery and patient engagement processes.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.

Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Ivenix is a medical technology company that develops a next-generation infusion management system. It is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals. The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow. The company was founded in 2007 and is headquartered in Amesbury, Massachusetts.

TraceLink, Inc. specializes in providing track and trace network solutions that enhance the life sciences supply chain and combat counterfeit prescription drugs. The company offers a range of products, including pharmaceutical serialization, drug tracking, and compliance solutions through its TraceLink Life Sciences Cloud. Key offerings include the Smart Rx Manager, which helps healthcare providers comply with the European Union Falsified Medicines Directive, and Serialized Product Intelligence, a cloud application that utilizes serialization data to identify supply chain issues and optimize operations. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers, and has established strategic partnerships with notable firms such as Amazon and KPMG. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink also has offices in the United Kingdom, India, Singapore, and Brazil. The company's platform is recognized for its ability to deliver global connectivity and visibility across the pharmaceutical supply chain, ensuring compliance and improving operational efficiency.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Codeship Inc. is a provider of hosted continuous integration solutions that specialize in automating the build, testing, and deployment of Docker-based applications. Founded in 2011 and based in Boston, Massachusetts, with an additional office in Vienna, Austria, the company aims to streamline development cycles for software companies, thereby reducing the risk of bugs and fostering innovation. By managing the testing and release processes, Codeship allows developers to focus on creating better products more quickly. In January 2013, the company changed its name from Railsonfire Limited and, as of February 2018, operates as a subsidiary of CloudBees, Inc.

Toast, Inc. is a Boston-based company that specializes in developing a comprehensive point-of-sale and restaurant management platform tailored for the foodservice and hospitality industries. Founded in 2011, Toast provides cloud-based solutions that include online ordering, delivery tracking, tableside ordering, and labor management, all designed to streamline restaurant operations. The platform serves a diverse range of establishments, including restaurants, cafés, bars, and nightclubs, enabling them to enhance customer experiences and optimize business performance. By offering software subscription services, processing transaction fees, and providing financing through its Toast Capital division, Toast supports over 120,000 restaurant locations across the United States. The company stands out by processing a significant volume of financial transactions on its platform, reinforcing its commitment to delivering a robust and effective technology solution for restaurateurs.

Codeship Inc. is a provider of hosted continuous integration solutions that specialize in automating the build, testing, and deployment of Docker-based applications. Founded in 2011 and based in Boston, Massachusetts, with an additional office in Vienna, Austria, the company aims to streamline development cycles for software companies, thereby reducing the risk of bugs and fostering innovation. By managing the testing and release processes, Codeship allows developers to focus on creating better products more quickly. In January 2013, the company changed its name from Railsonfire Limited and, as of February 2018, operates as a subsidiary of CloudBees, Inc.

PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.

Kyruus, Inc. is a provider of web-based software solutions focused on optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010 and headquartered in Boston, Massachusetts, Kyruus offers a suite of analytically driven products designed to enhance the engagement, management, and performance of healthcare providers. Its solutions include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which provides administrators with tools to monitor and analyze physician performance. Additionally, the company offers Kyruus MDSeekyr for identifying high-value providers and Kyruus Insight Reports for evaluating physician network trends and performance. The ProviderMatch suite further aids hospitals in connecting patients with the most suitable providers, ensuring a seamless patient experience while aligning provider availability with patient demand. Through its proprietary data management platform, Kyruus leverages accurate data to facilitate effective appointments and enhance overall patient care.

Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.

Ivenix is a medical technology company that develops a next-generation infusion management system. It is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals. The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow. The company was founded in 2007 and is headquartered in Amesbury, Massachusetts.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancermore

Unum Therapeutics is a biopharmaceutical company focused on developing immunotherapy products for cancer treatment, utilizing proprietary T-cell engineering technology. The company’s lead programs, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, are in Phase I clinical trials. These include ACTR707 and ACTR087, both being tested in combination with rituximab for relapsed or refractory CD20+ non-Hodgkin lymphoma, as well as ACTR087 combined with SEA-BCMA for relapsed multiple myeloma. Additionally, ACTR707 is being evaluated with trastuzumab for HER2+ solid tumors. Unum Therapeutics is also exploring BOXR1030, a pre-clinical candidate targeting glypican-3 to enhance T cell functionality in the solid tumor microenvironment. Founded in 2014 and headquartered in Cambridge, Massachusetts, Unum aims to activate the body’s immune system to effectively combat cancer through its innovative therapies.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for serious women's health infections, particularly bacterial vaginosis (BV). Founded in 2012, the company is based in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut. Its lead product, Solosec (secnidazole), is a novel 5-nitroimidazole antibiotic designed for a one-time oral treatment of bacterial vaginosis, addressing a significant unmet need in women's healthcare. Symbiomix operates as a subsidiary of Lupin Inc. and is supported by prominent healthcare venture capital firms. The company aims to provide effective therapeutic options for gynecologic infections that have been historically overlooked.

Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

TraceLink, Inc. specializes in providing track and trace network solutions that enhance the life sciences supply chain and combat counterfeit prescription drugs. The company offers a range of products, including pharmaceutical serialization, drug tracking, and compliance solutions through its TraceLink Life Sciences Cloud. Key offerings include the Smart Rx Manager, which helps healthcare providers comply with the European Union Falsified Medicines Directive, and Serialized Product Intelligence, a cloud application that utilizes serialization data to identify supply chain issues and optimize operations. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers, and has established strategic partnerships with notable firms such as Amazon and KPMG. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink also has offices in the United Kingdom, India, Singapore, and Brazil. The company's platform is recognized for its ability to deliver global connectivity and visibility across the pharmaceutical supply chain, ensuring compliance and improving operational efficiency.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

Flywire operates an online payment platform that facilitates both domestic and international transactions, catering primarily to the education and healthcare sectors. The platform enables users, including international students and patients seeking medical care abroad, to make payments in various currencies through familiar online and offline options. By leveraging vertical-specific insights and technology, Flywire streamlines the payment process and enhances operational efficiency while minimizing risks associated with invoicing and payment reconciliation. The company, which was founded in 2009 and is headquartered in Boston, Massachusetts, has established partnerships with TRUE North and Adyen to bolster its offerings. With a significant portion of its revenue generated from the Americas, Flywire continues to expand its services to meet the needs of its diverse clientele.

Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune-evasion. Surface is based in Cambridge, Mass.

Unum Therapeutics is a biopharmaceutical company focused on developing immunotherapy products for cancer treatment, utilizing proprietary T-cell engineering technology. The company’s lead programs, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, are in Phase I clinical trials. These include ACTR707 and ACTR087, both being tested in combination with rituximab for relapsed or refractory CD20+ non-Hodgkin lymphoma, as well as ACTR087 combined with SEA-BCMA for relapsed multiple myeloma. Additionally, ACTR707 is being evaluated with trastuzumab for HER2+ solid tumors. Unum Therapeutics is also exploring BOXR1030, a pre-clinical candidate targeting glypican-3 to enhance T cell functionality in the solid tumor microenvironment. Founded in 2014 and headquartered in Cambridge, Massachusetts, Unum aims to activate the body’s immune system to effectively combat cancer through its innovative therapies.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancermore

Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.

Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Kensho Technologies, Inc. is a data analytics and machine intelligence company that specializes in providing advanced analytics, artificial intelligence, and machine learning solutions to banks and investment institutions worldwide. Founded in 2013 and based in Cambridge, Massachusetts, with additional offices in New York, Virginia, and California, Kensho develops a suite of financial analytics software designed to enhance decision-making across the financial sector. Its flagship product incorporates natural language processing, enabling users to pose complex financial questions in plain English and receive actionable insights. The company also offers Kensho Applied Mind, an AI-driven software, and operates a national security division called Koto. Kensho's team comprises experts from prestigious backgrounds, including alumni from MIT, Harvard, Google, and the United States Federal Reserve, underscoring its commitment to addressing the challenges of speed, scale, and automation in investment analysis. Since its incorporation, Kensho has positioned itself as a key player in solving some of the most demanding analytical problems faced by both government and commercial entities.

ownCloud, Inc. develops a universal file access platform that allows organizations to host their own file sync and share solutions in their data centers or on cloud storage, ensuring compliance with regulatory requirements. The company's flagship product, ownCloud, is an open-source software solution that facilitates data access, management, and sharing across various devices, including desktop and mobile platforms. This self-hosted server enables users to collaborate securely with internal and external parties without relying on public cloud storage. ownCloud serves a diverse range of industries, including financial services, healthcare, government, and education, providing solutions for file synchronization, federated cloud sharing, and integration with SharePoint. Founded in 2011, ownCloud, Inc. is headquartered in Lexington, Massachusetts, with an international presence in Germany.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating cancers and rare diseases driven by genomic abnormalities. The company’s pipeline includes avapritinib, which targets systemic mastocytosis and gastrointestinal stromal tumors, and BLU-263, an oral KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders. Additionally, fisogatinib is in Phase I trials for advanced hepatocellular carcinoma, while pralsetinib targets RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Other investigational compounds include BLU-782, aimed at treating fibrodysplasia ossificans progressive. Established in 2008 and based in Cambridge, Massachusetts, Blueprint Medicines utilizes its proprietary chemical library and Insights-to-Validation Platform to develop personalized therapies that address specific molecular drivers of cancer and the challenges posed by resistance mechanisms. The company has formed collaboration agreements with several pharmaceutical entities to enhance its research and development efforts.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

WellAir Group Limited specializes in designing and manufacturing portable air disinfection units, HVAC air purification devices, and sensors aimed at improving indoor air quality. The company's products effectively remove airborne pollutants and pathogens, including viruses, bacteria, allergens, and mold. WellAir markets its offerings under the Novaerus and Plasma-Air brand names, serving a diverse clientele that includes hospitals, senior living facilities, schools, casinos, railway stations, residences, and industrial facilities. Its Novaerus Portables are medical-grade air disinfection units that deactivate airborne pathogens while neutralizing volatile organic compounds. The Plasma-Air HVAC systems utilize plasma-generated bipolar ionization to diminish particulate matter, odors, viruses, and bacteria. Additionally, WellAir manufactures sensors and provides a web-based monitoring portal that tracks outdoor air pollution, flu levels, pollen counts, and weather conditions. Founded in 2012 and based in Dublin, Ireland, WellAir is dedicated to creating safe indoor environments for the health and well-being of individuals.